TriangleGlofitamab (NCT06213311)
Glofitamab trial for B Cell Lymphoma (NCT06213311). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CD19-positive and CD20-positive large B-cell lymphoma that resisted first-line chemoimmunotherapy or returned within twelve months. Prior CAR-T therapy or glofitamab excludes participation.
The idea: combine axicabtagene ciloleucel with glofitamab. The cell treatment modifies the patient's T cells to target CD19; glofitamab connects T cells to CD20-positive cancer cells. The regimen also includes obinutuzumab pretreatment. Glofitamab doses increase in steps. Initial glofitamab and cell therapy require hospitalization. Researchers assess safety and complete responses.
This phase 2 study plans 40 patients. Jason Westin leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.